SNDX · Syndax Pharmaceuticals Inc · Webcasts, Transcripts & Audio
$8.72
-0.41 (-4.49%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Market Cap
$778.67M
Shares
89.30M
Volume · Nov 20
2.18M
Avg daily vol (3M)
2.61M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Syndax Pharmaceuticals Inc Webcasts
Earnings calls, investor updates, investor days and conferences for Syndax Pharmaceuticals Inc (SNDX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-02
Syndax Pharmaceuticals Inc (SNDX) Q3 2026 Earnings Call
Revenue
$83.30M
▲ 81.6% YoY Diluted EPS
$-0.55
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-08-04
Syndax Pharmaceuticals Inc (SNDX) Q2 2026 Earnings Call Transcript
Positive tone
RevuForge (menin inhibitor) commercial performance
Upcoming clinical data catalysts
Pipeline assets / new clinical programs
Revenue
$72.79M
▲ 91.8% YoY Diluted EPS
$-0.55
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-04-30
Syndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call
Revenue
$64.86M
▲ 223.6% YoY Diluted EPS
$-0.48
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Syndax Pharmaceuticals Inc (SNDX) Q4 2025 Earnings Call Transcript
Confident tone
Revuforj (revumenib) commercial launch and growth
NPM1 mutated AML indication expansion
Niktimvo (axatilimab) in chronic GVHD
Revenue
$68.48M*
▲ 791.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Syndax Pharmaceuticals Inc (SNDX) Q3 2025 Earnings Call Transcript
Confident tone
Revuforj commercial launch and demand momentum
NPM1 label expansion and NCCN guideline inclusion
KMT2A penetration and post-transplant maintenance
Revenue
$45.87M
▲ 267% YoY Diluted EPS
$-0.70
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Syndax Pharmaceuticals Inc (SNDX) Q2 2025 Earnings Call Transcript
Confident tone
Revuforj (revumenib) commercial launch
Niktimvo (chronic GVHD) launch
Menin inhibitor pipeline / frontline opportunity
Revenue
$37.96M
▲ 984.5% YoY Diluted EPS
$-0.83
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Syndax Pharmaceuticals Inc (SNDX) Q1 2025 Earnings Call Transcript
Confident tone
Niktimvo commercial launch
Revuforj commercial launch
Menin inhibitor first-mover leadership
Revenue
$20.04M
Diluted EPS
$-0.98
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-03
Syndax Pharmaceuticals Inc (SNDX) Q4 2024 Earnings Call Transcript
Confident tone
Revuforj launch and commercial uptake
Combination trials and clinical development pipeline
Niktimvo launch in chronic GVHD
Revenue
$7.68M*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-05
Syndax Pharmaceuticals Inc (SNDX) Q3 2024 Earnings Call Transcript
Confident tone
Revumenib regulatory progress
Frontline combination strategy
Niktimvo FDA approval and launch
Revenue
$12.50M
Diluted EPS
$-0.98
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Syndax Pharmaceuticals Inc (SNDX) Q2 2024 Earnings Call Transcript
Confident tone
Axatilimab launch in chronic GVHD
Revumenib FDA approval and PDUFA delay
Combination data presentations at EHA
Revenue
$3.50M
Diluted EPS
$-0.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Syndax Pharmaceuticals Inc (SNDX) Q1 2024 Earnings Call Transcript
Confident tone
revumenib regulatory and clinical progress
Commercial launch preparation
axatilimab regulatory progress
Revenue
$0
Diluted EPS
$-0.85
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Syndax Pharmaceuticals Inc (SNDX) Q4 2023 Earnings Call Transcript
Confident tone
Revumenib (menin inhibitor) pivotal data and NDA
Axatilimab in chronic GVHD approval
Combination strategies for revumenib
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Syndax Pharmaceuticals Inc (SNDX) Q3 2023 Earnings Call Transcript
Revenue
$0
Diluted EPS
$-0.73
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Syndax Pharmaceuticals Inc (SNDX) Q2 2023 Earnings Call Transcript
Revenue
$0
Diluted EPS
$-0.64
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Syndax Pharmaceuticals Inc (SNDX) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.59
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Syndax Pharmaceuticals Inc (SNDX) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Syndax Pharmaceuticals Inc (SNDX) Q3 2022 Earnings Call Transcript
Diluted EPS
$-0.58
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Syndax Pharmaceuticals Inc (SNDX) Q2 2022 Earnings Call Transcript
Diluted EPS
$-0.62
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Syndax Pharmaceuticals Inc (SNDX) Q1 2022 Earnings Call Transcript
Diluted EPS
$-0.63
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Syndax Pharmaceuticals Inc (SNDX) Q4 2021 Earnings Call Transcript
Revenue
$126.58M*
▲ 33209.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-15
Syndax Pharmaceuticals Inc (SNDX) Q3 2021 Earnings Call Transcript
Revenue
$12.38M
▲ 3165.2% YoY Diluted EPS
$-0.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Syndax Pharmaceuticals Inc (SNDX) Q2 2021 Earnings Call Transcript
Revenue
$379,000
▲ 0% YoY Diluted EPS
$-0.44
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-11
Syndax Pharmaceuticals Inc (SNDX) Q1 2021 Earnings Call Transcript
Revenue
$379,000
▲ 0% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-08
Syndax Pharmaceuticals Inc (SNDX) Q4 2020 Earnings Call Transcript
Revenue
$380,000
▲ 0% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-02
Syndax Pharmaceuticals Inc (SNDX) Q3 2020 Earnings Call Transcript
Revenue
$379,000
▲ 0% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Syndax Pharmaceuticals Inc (SNDX) Q2 2020 Earnings Call Transcript
Revenue
$379,000
▲ 0% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
Syndax Pharmaceuticals Inc (SNDX) Q1 2020 Earnings Call Transcript
Revenue
$379,000
▲ 0% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-03
Syndax Pharmaceuticals Inc (SNDX) Q4 2019 Earnings Call
Revenue
$380,000
▲ 0% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 webcasts
Key facts
CIK
1395937
CUSIP
87164F105
13F (30d)
241 filings
222 filers
Visit website
Investor relations